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Abstract
This research examined whether pediatric inpatients without an anxiety/mood disorder are more
likely to receive opioids in response to pain compared to patients diagnosed with a mental health
condition. Research questions were tested using cross-sectional inpatient electronic medical
record data. Propensity score matching was used to match patients with a disorder with patients
without the disorder (anxiety analyses: N = 2,892; mood analyses: N = 1,042). Although patients
with anxiety and mood disorders experienced greater pain, physicians were less likely to order
opioids for these patients. Analyses also disclosed an interaction of anxiety with pain—the painopioid relation was stronger for patients without an anxiety disorder than for patients with an
anxiety diagnosis. Instead, physicians were more likely to place non-opioid analgesic orders to
the manage the pain of patients with anxiety disorders. Findings imply that pain management
decisions might be influenced by patient mental health.
Keywords: opioids; pediatric pain; pain management; mood disorders; anxiety disorders
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Introduction
The opioid epidemic has emerged as a public health crisis in the U.S., with about 47,000
Americans dying from an opioid-related overdose annually (Center for Disease Control and
National Center for Health Statistics, 2018). Children and adolescents have also been impacted
by this opioid epidemic. A study of pediatric deaths from opioids suggests a 268.2% increase in
mortality rates between 1999-2016 (Gaither, Shabanova, & Leventhal, 2018), with
approximately 16.2% of all emergency department visits for patients ages 13 – 17 being
associated with opioid use (Tomaszewski, Arbuckle, Yang, & Linstead, 2018). Nationally, about
3.6% of adolescents between the ages of 12 and 17 report misusing an opioid in the past year
(Substance Abuse and Mental Health Services Administration, 2017). This is troubling, as
initiating opioid misuse between the ages of 10 and 12 years old has been linked with a high risk
of transitioning to heroin use in adolescence and young adulthood (Cerdá, Santaella, Marshall,
Kim, & Martins, 2015).
Despite this risk of opioid misuse and its adverse consequences, research on the
legitimate use of prescribed opioids in pediatric patients is relatively scarce. Notably, prescribed
opioid use from a physician in a pediatric hospital setting has been identified as a risk factor of
youth opioid misuse (McCabe et al., 2017). A national study showed that legitimate opioid use
during adolescence was associated with a 33% increase in the risk of future nonmedical use
during young adulthood (Miech, Johnston, O’Malley, Keyes, & Heard, 2015). Similarly,
pediatric patients prescribed opioids for postoperative pain have been shown to be at risk for
persistently using opioids 3 to 6 months after the surgical recovery period (Harbaugh et al.,
2018). Given the link between medical opioid use with misuse (McCabe et al., 2017) and
persistent use (Edlund et al., 2014), researchers have begun to assess the relationship between
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pain and opioid prescribing in both the outpatient (Donaldson et al., 2020; Kain et al., 2020) and
hospital setting (Womer et al., 2014).
Pain in hospitalized children is common (Friedrichsdorf et al., 2015), with about 27% of
pediatric patients experiencing moderate to severe pain (Groenewald, Rabbitts, Schroeder, &
Harrison, 2012). Specifically, pain is defined as “an unpleasant sensory and emotional
experience, associated with actual or threatened tissue damage, or described in terms of
such”(International Association for the Study of Pain, 1994), signifying that pain is a cognitive,
and emotional response to nociception (Bushnell, Čeko, & Low, 2013). However, the intensity of
pain experienced can greatly vary for a given noxious stimulus based on the interactive effects of
biological (e.g., genetics), psychological (e.g., distress, emotions, coping strategies), and social
(e.g., culture, family relationships) factors (Rahim-Williams, Riley, Williams, & Fillingim, 2012;
Taylor, 2015).
A link between anxiety and depression severity with pain has been established in both
adult and pediatric samples. In a longitudinal study with adult patients being treated for chronic
musculoskeletal pain and depression, Bair and associates (2013) found that baseline anxiety
symptomology predicted pain during a 12 month follow-up assessment. Specifically, patients
scoring higher on the Generalized Anxiety Disorder scale (Spitzer, Kroenke, Williams, & Löwe,
2006) reported greater pain severity one year later. Similar trends have been found for pediatric
patients. Stanford and associates (2008) showed that depression and anxiety severity were
associated with recurrent head, stomach, and back pain in a sample of 10 to 11 year old
respondents followed longitudinally overtime. In contrast, the diagnostic relationship between
common psychiatric disorders (e.g., anxiety and depression) with pain is less understood. Dorn et
al. (2003) conducted a cross-sectional study with children and adolescents between the ages of 8
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and 16 and found that 50% of youth with recurrent abdominal pain met the diagnostic criteria for
an anxiety disorder. However, additional research is needed to better understand differences in
pain severity based on the presence or absence of a mental health disorder.
Opioid use is also associated with mental health in adult patients. Specifically, previous
studies advocate that adults with mental health co-morbidities have a higher likelihood of
receiving an opioid prescription (Davis, Lin, Liu, & Sites, 2017) and regularly using prescription
opioids (Halbert, Davis, & Wee, 2016; Sullivan, Edlund, Zhang, Unützer, & Wells, 2006).
Research (Goesling et al., 2015) also suggests that pain and mental health might interact to
influence opioid prescribing and use. Goesling and associates (2015) examined the relationship
between pain and opioid use in depressed adults with chronic pain, and found that depression
moderated the pain-opioid use relationship. For patients with no depressive symptoms, there was
a positive association between pain severity and opioid use. However, for patients with
symptoms of depression, there was no significant relationship between pain severity and opioid
use.
In adolescents, studies have established a link between adolescent depression with opioid
misuse (Havens, Young, & Havens, 2011), persistent use (Whiteside et al., 2016), and abuse
(Edlund et al., 2015). However, the relationship between pain and opioid prescribing for
pediatric patients diagnosed with anxiety and mood diagnoses has been understudied
(Groenewald, Zhou, Palermo, & Van Cleve, 2019; Quinn et al., 2018). Quinn and associates
(2018) investigated relationships between mental health and opioid prescribing using a database
of commercial insurance claims. In this study, patients with anxiety and mood disorders were
more likely to be prescribed a prescription opioid and to receive long-term opioid therapy.
Similarly, Groenewald et al. (2019) found that anxiety and mood disorders were related with an
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increased risk of opioid overdose in a retrospective analysis of privately insured adolescent
patients. Still, despite the utility of these studies, there is a lack of research assessing statistical
interactions between pain severity and diagnosis on the prescription of opioid medications in one
multivariable model for pediatric inpatients.
Given this gap in the literature, research examining differences in pain and opioid use
based on mental health in a pediatric inpatient setting is important for encouraging appropriate
and safe pain management across diverse groups, before patients develop future problems with
misuse and persistent use. As such, the current study aims to determine whether differences in
pain and physician opioid ordering exist for patients with mental health comorbidities, and
whether, the relationship between pain and opioids differs based on mental health diagnosis
during the patient's visit. It is hypothesized that patients diagnosed with anxiety and mood
disorders during their inpatient stay will experience higher levels of pain during their hospital
admission. Additionally, the presence or absence of an anxiety/mood disorder diagnoses is
postulated to moderate the relationship between inpatient pain and the number of opioid
medications ordered (Goesling et al., 2015). Specifically, patients without an anxiety or mood
disorder diagnosis are anticipated to be more likely to receive opioid orders in response to
clinically significant pain compared to patients with a mental health diagnosis.
Method
Data Source
Research questions were assessed using cross-sectional inpatient encounter data from
June 2013 to June 2018 that was retrieved from a pediatric children's hospital. Electronic medical
record information (EMR) was extracted from pediatric patients between the ages of 0 and 18 (N
= 81,018) that were admitted as inpatients across a variety of care settings and were prescribed
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medication to manage pain. Records were de-identified and patients were assigned a unique
encounter identifier, allowing medical record information to be linked.
Inclusion Criteria and Data Cleaning
Given the low prevalence of anxiety and mood disorders in patients under the age of 2,
only patients between the ages of 2 and 18 were included in the analysis (N = 63,195). Further,
the objective of this research was to examine differences in opioid prescribing for patients
without cancer-associated chronic pain; thus, information on neoplasms was extracted using
International Classification of Diseases, Ninth/Tenth revision (ICD-9/10), Clinical Modification
codes C00 through D49. Patients with neoplasms (n = 8,017) were identified using the diagnosis
codes and excluded from the analyses (Chung et al., 2018; Richardson et al., 2011). Patient
length of stay was then examined for outliers. Patients in the 99th percentile (n = 647) were
excluded from the remaining analyses (N = 54,531).
Variables
Pain severity. Patient pain is assessed by healthcare providers throughout the in-patients’
hospital stay using several developmentally and situationally appropriate measurement tools (i.e.,
Faces, Legs, Activity, Cry, and Consolability scale [Voepel-Lewis, Merkel, Tait, Trzcinka, &
Malviya, 2002], Faces Pain Scale [Hicks, von Baeyer, Spafford, van Korlaar, & Goodenough,
2001], Numeric Rating Scale [Miró, Castarlenas, & Huguet, 2009], and Neonatal Pain, Agitation
and Sedation Scale [Hummel, Puchalski, Creech, & Weiss, 2008]). For the purpose of the
present study, patient maximum pain score ratings during the hospital stay were included in the
analyses (as done in Ehwerhemuepha, Schultz, & Feaster, 2018). Across all scales, pain level
ranged from 0 (no pain) to 10 (high pain). Additionally, pain score was standardized (using a zscore) in the final analysis.
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Anxiety and mood disorder diagnosis. Anxiety and mood disorders were diagnosed by
the patient's provider during their inpatient visit. Patients were classified as having a mental
health disorder if they displayed the symptoms presented in Table 1. Using the ICD-9/10 coding
system, and grouping strategy implemented in prior studies (see Carballo et al., 2010; Pedersen
et al., 2014; Waghorn, Chant, White, & Whiteford, 2005), patients were categorized as having an
anxiety disorder if they were diagnosed with at least one of the following conditions during their
inpatient visit: phobic and social anxiety disorders (F40-F40.9); generalized anxiety, panic
disorder, and other anxiety disorders (F41-F41.9), stress-related and adjustment disorders (F43F43.9); and somatoform disorders (F45-F45.9). Patients were classified as having a mood
disorder diagnosis if they were diagnosed with one or more of the following conditions during
their visit: manic episode (F30-F30.9); bipolar disorder (F31-F31.9); major depressive disorder
(F32-F33.9); persistent mood disorders (F34-F34.9); and unspecified mood disorder (F39).
Opioid and non-opioid analgesic medication orders. The primary outcome variable
examined in this research was the number of opioid orders made by the patient's provider during
a single patient hospitalization encounter, regardless of the quantity/dose of the medication per
order (as done in Ehwerhemuepha et al., 2020). Specifically, this variable represented the total
number of opioids requested by the physician. Opioids included codeine, hydrocodone,
hydromorphone, meperidine, sufentanil, fentanyl, morphine, oxycodone, remifentanil,
nalbuphine, methadone, and tramadol. A sum of the total number of opioid analgesic
medications ordered was computed as a sum score across all the different possible opioid types
to indicate the total number of opioids ordered. Patients with more than one opioid order could
have had the same opioid medication ordered multiple times, multiple opioid medications, or a
combination of the two. In addition, information on the number of non-opioid analgesics (e.g.,
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ibuprofen, acetaminophen, naproxen, gabapentin, pregabalin, celecoxib, triptan) orders was
calculated in the same way.
Covariates. Information on admittance year, age, sex, race/ethnicity (Hispanic/Latinx
versus all others), insurance (Medicare/Medi-Cal versus all other insurance types), and length of
stay were included in all analyses as control variables. Patient visit diagnoses were also retrieved
and controlled for using the ICD-9/10 coding system (see Table 2).
Data Analytic Strategy
Propensity score case-control matching was performed using R's "MatchIt" package (Ho,
Imai, King, & Stuart, 2011). The nearest neighbor matching algorithm with a caliper width set =
0.2 of the SD of the logit of the propensity score was implemented (Austin, 2011). Both the
anxiety and mood disorder diagnoses were submitted to a propensity score matching procedure.
The propensity that each participant received a diagnosis of an anxiety or mood disorder was
calculated using a regression model that included the demographic and visit medical diagnosis
covariates. “Case” (presence of an anxiety/mood disorder) and “Control” (absence of an
anxiety/mood disorder) sets of patients were matched based on the resulting propensity scores.
Matching was conducted without replacement. All patients who were not matched in the
propensity score procedure was excluded from subsequent analyses. Following the
recommended guidelines (Zhang, Kim, Lonjon, & Zhu, 2019), the standardized mean difference
of covariates before and after matching was calculated and assessed to diagnose the balance each
covariate distribution between the case and control groups.
Two separate Poisson regression models assessed the relationships between
anxiety/mood disorder diagnoses with medication ordering using the propensity score matched
samples. A linear multiple regression model assessed the association of pain level with
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medication ordering. Admission year, demographic variables, and visit diagnosis covariates were
controlled for in all analyses. All variables were standardized using z-scores in the final model.
The graphing and interpretation of the interaction terms followed recommended procedures
(Aiken & West, 1991). The simple slope of maximum pain score was graphed on the
anxiety/mood disorder moderator at one standard deviation below the mean, at the mean, and one
standard deviation above the mean.
Results
Descriptive information on the final samples is displayed in Table 3. The earliest age of
onset for all mental health conditions was 2 years old. Overall, 2.90% (n = 1,586) of the sample
was diagnosed with a clinical anxiety disorder and 1.30% (n = 711) were diagnosed with a mood
disorder during their inpatient visit (see Tables 2 and 3). Approximately 92.60% of patients
classified as having an anxiety disorder and 95.2% of patients with recorded as having a mood
disorder were diagnosed with at least one other diagnostic condition during their inpatient
admission. Furthermore, 140 cases could not be matched in the anxiety disorder matching
procedures and 190 were unmatched in the mood disorder matching analysis. Large group
differences in the demographic and diagnosis covariates across diagnosis groups were largely
eliminated in the propensity score case-control matching.
Multivariate Regression Models
Pain severity. The multivariate regression models examining the effect of anxiety (Table
4) and mood (Table 5) disorders on pain severity, showed that after controlling for all
demographic and diagnosis covariates, patients diagnosed with an anxiety and/or mood disorder
(both p < .001) expressed higher pain levels during their hospitalization.
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Ordered opioid analgesics. The model testing the effect of anxiety on ordered opioid
analgesics (Table 4), indicated that physicians ordered fewer opioids for patients with lower pain
scores and anxiety disorders (both p < .001). There was also a significant interaction of pain and
anxiety diagnosis (p < .001; Figure 1). The relationship between pain and the number of opioids
ordered was stronger for patients without an anxiety disorder (β = 0.21, SE = 0.01, p < .001),
than for patients with an anxiety disorder (β = 0.16, SE = 0.01, p < .001). When patients
expressed high pain levels (+1SD above the mean), physicians placed an average of 2.53 opioid
orders for patients without anxiety and 1.83 orders for those with an anxiety disorder diagnosis.
Thus, although patients with anxiety disorders expressed greater pain, physicians ordered
32.11% more opioids for patients without anxiety diagnoses. In contrast to the anxiety disorder
findings, the model examining the effect of mood on ordered opioid analgesics (Table 5), did not
reveal a significant interaction of pain level and mood disorder. Instead, findings disclosed
significant main effects of pain and a mood disorder diagnosis, indicating that patients with
lower pain scores and mood disorders (both p < .001) received fewer opioids.
Ordered non-opioid analgesics. The regression model scrutinizing the impact of anxiety
on ordered non-opioid analgesics (Table 4), showed that physicians ordered a greater number of
non-opioids for patients with higher pain scores (p < .001). There was also a significant
interaction of pain and anxiety disorder diagnosis (p < .001; Figure 2)—the relationship between
pain and the number of non-opioids ordered was stronger for patients with an anxiety disorder (β
= 0.10, SE = 0.01, p < .001), than for patients without an anxiety diagnosis, (β = 0.07, SE = 0.01,
p < .001). When patients expressed high pain, physicians ordered 2.61 non-opioid medications
for patients without an anxiety disorder and 2.96 non-opioid analgesics for patients with anxiety
disorders (representing a 12.57% difference). The model analyzing the effect of mood on ordered
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non-opioids (Table 5), showed that pain score was associated with non-opioid orders (p < .001).
The main effect of mood disorder diagnosis and the interaction with pain were not statistically
significant.
Auxiliary Analysis
Although visit diagnosis was controlled for in all analyses, a possible alternative
explanation of the presented findings is that patient medical diagnosis confounded the results.
Findings in both analyses revealed that patients diagnosed with diseases of the musculoskeletal
system and connective tissue (M00-M99) and/or injury, poisoning and certain other
consequences (S00-T88) were more likely to receive an opioid order than patients without these
diagnoses. In response, an auxiliary analysis was conducted with a subset of patients with these
two diagnostic classifications (N = 11,501). Within this selected sample, 4.60% (n = 526) had an
anxiety disorder diagnosis and 3.00% (n = 344) were classified as having a mood disorder. The
same analytic plan incorporating propensity score case-control matching used in the main
analysis was implemented. Three hundred and thirty six patients were matched in the anxiety
disorder analysis; 141 were matched in the mood disorder analysis.
The model testing the effect of anxiety on ordered opioid analgesics for patients with
diseases of the musculoskeletal system and connective tissue, and/or injury, poisoning and
certain other consequences (N = 672) revealed a significant interaction of pain and anxiety
diagnosis (β = -0.13, p < .001). Findings replicated the main analyses—the relationship between
pain and opioids orders was stronger for patients without an anxiety disorder (β = 0.12, SE =
0.01, p < .001), than for patients with an anxiety disorder (β = 0.08, SE = 0.02, p < .001). The
model testing the effect of mood disorders on ordered opioid analgesics for the selected subset of
patients (N = 282) disclosed a main effect of mood diagnosis (β = -0.18, p < .01), suggesting that
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patients diagnosed with a mood disorder received fewer prescribed opioids regardless of pain
severity.
Discussion
Under the conditions of this study, pediatric inpatients with anxiety and mood disorders
were rated as having greater pain severity during their admittance as an inpatient in a hospital
setting. Physicians also ordered fewer opioids for patients diagnosed with anxiety and mood
disorders. Additionally, for patients diagnosed with an anxiety, physicians were less likely to
place opioid orders in response to severe pain, and were instead more likely to place non-opioid
analgesic orders to the manage significant pain severity.
These findings are consistent with past studies conducted among adult patients
demonstrating a link between mental health with pain severity and frequency (Bair, Robinson,
Katon, & Kroenke, 2003; Stanford et al., 2008). Current theoretical explanations propose an
interplay of biological, emotional, and cognitive factors for explaining relationships between
mental health conditions and the experience of pain (Weersing, Rozenman, Maher-Bridge, &
Campo, 2012). Specifically, anxious youth might be biologically sensitive to stress (Biederman
et al., 1993), demonstrating overactivity in brain regions used to suppress fight or flight response
(Mathew, Coplan, & Gorman, 2001). Similarly, theories of pain for individuals diagnosed with
depression imply a genetic vulnerability to mood dysregulation when faced with stressful life
events (Caspi et al., 2003). Anxious and depressed individuals may experience heightened levels
of anticipation and hypervigilance to threatening cues (Mogg & Bradley, 2005; Simpson, Neria,
Lewis-Fernández, & Schneier, 2010), increasing the severity of pain experienced. Youth
diagnosed with mood and anxiety disorders might also exhibit inaccurate, overly threatening
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(Barlow, 2004) or negative cognitive styles (Gladstone & Kaslow, 1995), impacting how they
perceive and express pain.
Although research with adults show that patients diagnosed with psychiatric disorders
have a higher likelihood of receiving a prescription for opioid analgesics (Davis et al., 2017;
Goesling et al., 2015), studies examining this association in pediatric patients is scarce
(Groenewald et al., 2019; Quinn et al., 2018). A previous investigation with pediatric patients
showed that being diagnosed with an anxiety or mood disorder was related with an increased
likelihood of opioid prescription (Quinn et al., 2018); but this study did not assess interactions
between pain severity and mental diagnosis on opioid prescribing in one multivariable model. In
contrast, the current research examined opioid orders and demonstrated that patients with mental
health diagnoses (anxiety and mood disorders) were less likely to receive prescription opioids
when controlling for pain.
Together with prior studies on mental health and pediatric opioid use (Groenewald et al.,
2019; Quinn et al., 2018), the complex results of this investigation support that the decision to
order or prescribe a prescription opioid is complicated, and relies on the interaction of patient,
provider, medical, and social factors (Turk & Okifuji, 1997). For example, the finding that
physicians were less likely to order prescription opioid medications to treat severe pain in
patients perceived to have a mental health disorder is not surprising, as there is an established
relationship between prescription opioid use and later misuse in adolescent patients (Miech et al.,
2015). As such, it is logical that physicians might decide to be more conservative when deciding
whether to order opioid analgesics over non-opioid alternatives in this setting. Also, within the
context of the opioid epidemic, governmental and professional organizations have implemented
programs designed to monitor and implement consistent clinical guidelines for opioid therapy,
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with guidelines recommending that physicians screen for mental health conditions prior to
prescribing opioid analgesics (Nuckols et al., 2014). The finding that physicians made fewer
opioid orders for pediatric inpatients with anxiety and mood disorders, even at high levels of
pain, might therefore support the influence of social factors on the decision to order opioid
medications.
A challenge with pain management is that no biological objective measure currently
exists to assess the efficacy of opioid treatment. Nurses and physicians must therefore interpret
patient pain experiences. The observed differences in ordered opioids might be explained by
patient, provider, psychological, and social factors that influence how health care providers
interpret pain and subsequently decide the best plan of management. Specifically, providers may
perceive that patients exhibiting symptoms of anxiety and mood disorders express exaggerated
pain levels due to feelings of psychological distress, worry, or depression (Hansen & Streltzer,
2005). If patient pain expression is perceived to be amplified due to the patient's current
psychological state (e.g., excessive worry, fear, or sadness), it is likely that providers would
decide to seek alternative lower risk pain management strategies. It is also important to highlight
that despite their possible negative side effects, opioids are shown to effectively help with acute
pain management (Manchikanti & Singh, 2008). Thus, patients with mental health disorders
should not completely be denied opioid analgesics for pain relief, as undermanagement of pain is
also a concern. Instead, future investigations should examine potential relationships between
inpatient opioid use and later opioid misuse, persistent use, and abuse, and the ways in which
parents can be educated about the risks of opioid use and safe storage behaviors (McDonald et
al., 2017).
Strengths and Limitations
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Findings should be interpreted in light of several limitations. Data were cross-sectional,
and as a result, causal conclusions about the relationship between mental health conditions and
physician opioid ordering could not be drawn. However, the use of propensity score matching
which is a casual inference technique aids in ameliorating this limitation. The current
investigation involved inpatients at a single tertiary pediatric institution. Although it is expected
that studies with inpatients from similar institutions would establish similar results, the current
findings might not be generalizable to all pediatric facilities. Although similar effects have been
found in prior secondary data analytic research examining substance use outcomes (Donaldson,
Nakawaki, & Crano, 2015), the low effect sizes in the main analyses might also represent a
limitation. Still, differences in opioid ordering were relatively large at high levels of pain
(representing a 33.45% difference in the anxiety analysis and a 51.90% difference in the mood
disorder analysis). Thus, findings are likely to have practical and clinical implications,
suggesting that physicians might possess biases outside of their awareness, and that patients with
mental health conditions might be suffering disproportionally from pain in a pediatric hospital
setting.
Previous research suggests that electronic medical record mental health diagnostic
information is not always accurate (Davis, Sudlow, & Hotopf, 2016). Consequently, the validity
of the anxiety and mood disorder diagnoses made by provider's during the patient's visit also
represents a study limitation. Regardless, provider perceptions were the focus of this work,
suggesting that diagnostic validity might not be as critical in this context. Instead, it is important
to highlight that when physicians perceived patients as exhibiting symptoms associated with
anxiety (see Table 1; e.g., persistent fear and worry) and mood (e.g., mood swings, elation,
sadness) disorders, they were less likely to order opioid medications. As such, findings imply
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that symptoms of mental health disorders influence provider willingness to prescribe opioid
analgesics.
The aim of this work was to examine physician prescribing decisions (under the
assumption that physicians ordered the appropriate medication dose). Thus, the examination of
opioid orders is appropriate in this setting, as opioid orders have been examined as a proxy for
opioid prescriptions in other studies of patient EMR data (Lail, Sequeira, Lieu, & Dhalla, 2014).
Still, the use of opioid orders represents both a strength and limitation. Most studies of opioid use
in this context have examined prescriptions or orders as a binary (yes/no) variable. A strength of
this research is the examination of opioid ordering as a continuous outcome. However, the use of
opioid order is also a limitation, as the number of opioids ordered did not necessarily reflect the
number of doses administered to patients. To offset this limitation, visit diagnoses were
controlled for in all analyses, and logistic regression models were estimated treating ordered
opioid analgesics as a binary outcome, which replicated the pattern of results revealed in this
study. Still, administered opioid dose represents a more accurate conceptualization of prescribing
patterns, and should therefore be examined in future studies with pediatric patients.
Conclusion
To the best of our knowledge, this is the first investigation to examine trends in opioid
prescribing for pediatric patients with mental health diagnoses that have been admitted as
inpatients and prescribed medication to manage pain. Results suggest that although patients with
anxiety and mood disorders experience more severe pain during their hospital stay, physicians
decide to make fewer prescription opioid analgesic orders for patients with these psychological
co-morbidities. Specifically, findings suggest that patients with anxiety and mood disorders are
less likely to be prescribed opioids, even after controlling for pain level, when compared with a
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matched sample of patients that did not have an anxiety/mood disorder. However, additional
research is needed to understand how opioid use as an inpatient is associated with adverse opioid
outcomes, especially in the pain context. Regardless, this work suggests that future studies
examining the association between mental health disorders and prescription opioid use are
warranted to promote safer and appropriate opioid use among pediatric populations.
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Figure Captions

Figure 1. Interaction of pain severity and anxiety disorder diagnosis on the number of opioid
analgesics ordered. Values reflect standardized estimates controlling for all model covariates and
95% confidence intervals. The number of ordered opioid analgesics ranged from 0 to 10, but was
truncated to maintain conceptual clarity.

Figure 2. Interaction of pain severity and anxiety disorder diagnosis on the number of non-opioid
analgesics ordered. Values reflect standardized estimates controlling for all model covariates and
95% confidence intervals. The number of ordered non-opioid analgesics ranged from 0 to 9, but
was truncated to maintain conceptual clarity.

Figure 1. Interaction of pain severity and anxiety disorder diagnosis on the number of opioid
analgesics ordered. Values reflect standardized estimates controlling for all model covariates and
95% confidence intervals. The number of ordered opioid analgesics ranged from 0 to 10, but was
truncated to maintain conceptual clarity.

Figure 2. Interaction of pain severity and anxiety disorder diagnosis on the number of non-opioid
analgesics ordered. Values reflect standardized estimates controlling for all model covariates and
95% confidence intervals. The number of ordered non-opioid analgesics ranged from 0 to 9, but
was truncated to maintain conceptual clarity.

Table 1. International Classification of Diseases, Ninth/Tenth revision (ICD-9/10) Mental Disorder
Diagnostic Classifications
ICD 9/10
n (%) of
Symptomsb
Codes
Casesa
Anxiety, dissociative, stress-related, and somatoform disorders (n = 1,586, 2.90%)
Phobic and
Intense, unrealistic, persistent fear and avoidance of
social anxiety
F40-F40.9 220 (0.4%)
an object, activity, or situation.
disorders
Generalized
Anxiety disorders: excessive worry and feelings of
anxiety, panic
fear, dread, and uneasiness that last six months or
disorder, and
F41-F41.9 741 (1.4%)
longer. Panic disorder: an anxiety disorder
other anxiety
characterized by multiple unexpected panic attacks
disorders
with persistent concern of recurring attacks.
Diagnosis

Stress-related
and adjustment
disorders

F43-F43.9

862 (1.6%)

Acute stress reaction and post-traumatic stress: the
development of anxiety and dissociative symptoms as
a result of exposure to a traumatic event. Adjustment
disorders: person responds to a stressful event (such
as an illness, job loss, or divorce) with extreme
emotions and actions.

Somatoform
disorders

F45-F45.9

304 (0.6%)

The presence of physical symptoms that suggest a
medical condition but are not fully explained by any
known medical reasons.

Mood [affective] disorders (n = 711, 1.30%)

Characterized by a period of at least one week where
an elevated, expansive, or unusually irritable mood.
Marked by severe mood swings (manic or major
Bipolar disorder F31-F31.9 250 (0.5%)
depressive episodes) and a tendency to remission and
recurrence.
Ongoing feelings of sadness, loss of energy, and
difficulty dealing with normal daily life. Other
symptoms include feelings of worthlessness and
Major depressive
F32-F33.9 571 (1.1%)
hopelessness, loss of pleasure in activities, changes in
disorder
eating or sleeping habits, and thoughts of death or
suicide.
Alternating and recurring periods of depression and
Persistent mood
elation. Also, can be characterized by relatively mild
F34-F34.9 247 (0.5%)
disorders
depressive symptoms or marked loss of pleasure in
usual activities.
Severe disturbance in mood (depression, anxiety,
Unspecified
F39
214 (0.4%)
elation) accompanied by psychotic symptoms such as
mood disorder
delusions, and hallucinations.
Note. The earliest age of onset for all disorders was 2 years old. Patients could be diagnosed with more
than one disorder. a = unmatched sample (N = 53,292); b = symptoms from the ICD 10 website:
https://www.icd10data.com/ICD10CM/Codes/F01-F99
Manic episode

F30-F30.9

201 (0.4%)

Table 2. Sample Characteristics Before and After Propensity Score Case-Control Matching
Anxiety Disorder Analysis
Before Matching
After Matching
(N = 54,531)
(N = 2,892)
No Diagnosis
(n = 52,945)

Yes Diagnosis
(n = 1,586)

No Diagnosis
(n = 1,446)

Yes Diagnosis
(n = 1,446)

M(SD)

M(SD)

M(SD)

M(SD)

Mood Disorder Analysis
Before Matching
After Matching
(N = 54,531)
(N = 1,042)
Yes
No Diagnosis
No Diagnosis Yes Diagnosis
Diagnosis
(n = 53,820)
(n = 521)
(n = 521)
(n = 711)
M(SD)
M(SD)
M(SD)
M(SD)

Age

9.64 (4.71)

12.84 (4.08)

12.82 (4.44)

12.83 (4.06)

9.68 (4.71)

13.88 (4.11)

13.89 (4.33)

14.69 (3.48)

Length of Stay

3.26 (3.98)
n(%)

6.01 (6.37)
n(%)

5.99 (6.69)
n(%)

6.03 (6.06)
n(%)

3.33 (4.07)
n(%)

4.54 (5.91)
n(%)

5.30 (6.12)
n(%)

5.28 (5.97)
n(%)

Year: 2013

3,478 (6.60)

76 (4.80)

29 (2.0)

56 ( 3.90)

3,485 ( 6.50)

69 ( 9.70)

27 ( 5.20)

22 ( 4.20)

8,639 (16.30)

130 (8.20)

119 (8.20)

100 ( 6.90)

8,652 (16.10)

117 (16.50)

57 (10.90)

62 (11.90)

11,320 (21.40)

154 (9.70)

231 (16.0)

140 ( 9.70)

11,356 (21.10)

118 (16.60)

104 (20.0)

89 (17.10)

11,746 (22.20)

455 (28.70)

331 (22.90)

424 (29.30)

12,044 (22.40)

157 (22.10)

123 (23.60)

131 (25.10)

11,873 (22.40)

602 (38.00)

450 (31.10)

570 (39.40)

12,295 (22.80)

180 (25.30)

147 (28.20)

155 (29.80)

5,889 (11.10)

169 (10.70)

286 (19.80)

156 (10.80)

5,988 (11.10)

70 ( 9.80)

63 (12.10)

62 (11.90)

28,451 (53.70)

678 (42.70)

618 (42.70)

635 (43.90)

28,892 (53.70)

237 (33.30)

202 (38.80)

169 (32.40)

840 (58.10)

861 (59.50)

28,943 (53.80)

442 (62.20)

320 (61.40)

326 (62.60)

743 (51.40)

742 (51.30)

21,156 (39.30)

308 (43.30)

219 (42.0)

227 (43.60)

Year: 2014
Year: 2015
Year: 2016
Year: 2017
Year: 2018
Male

Hispanic
28,430 (53.70)
955 (60.20)
Medicare/MediCal
20,641 (39.00)
823 (51.90)
Presence of the following visit diagnoses:
Anxiety Disorder ----Mood Disorder
343 ( 0.60)
368 (23.20)
Bacterial/viral
infections (A00A99)
4,488 ( 8.50)
321 (20.20)
Blood disease
(D50-D89)
6,823 (12.90)
374 (23.60)
Endocrine,
nutritional, and
metabolic
diseases (E00E89)
7,789 (14.70)
547 (34.50)

--186 (12.90)

--231 (16.0)

1,218 ( 2.30)
---

368 (51.80)
---

146 (28.30)
---

176 (34.0)
---

212 (14.70)

217 (15.0)

4,580 ( 8.50)

229 (32.20)

47 ( 9.0)

55 (10.60)

231 (16.0)

273 (18.90)

6,963 (12.90)

234 (32.90)

60 (11.50)

63 (12.10)

382 (26.40)

424 (29.30)

7,984 (14.80)

352 (49.50)

175 (33.60)

169 (32.40)

Nervous system
diseases (G00G99)
Circulatory
system diseases
(I00-I99)
Respiratory
system diseases
(J00-J99)
Digestive system
diseases (K00K95)
Diseases of the
musculoskeletal
system
/connective
tissue (M00M99)
Genitourinary
system diseases
(N00-N99)
Congenital
malformations,
deformations and
chromosomal
abnormalities
(Q00-Q99)
Injury/poisoning
(S00-T88)
Other mental,
behavioral and
neurodevelopme
ntal (F01-F99)

10,845 (20.50)

632 (39.80)

490 (33.90)

526 (36.40)

11,121 (20.70)

356 (50.10)

183 (35.10)

185 (35.50)

3,954 ( 7.50)

386 (24.30)

239 (16.50)

267 (18.50)

4,068 ( 7.60)

272 (38.30)

109 (20.90)

96 (18.40)

10,263 (19.40)

367 (23.10)

251 (17.40)

269 (18.60)

10,374 (19.30)

256 (36.0)

90 (17.30)

86 (16.50)

15,304 (28.90)

519 (32.70)

398 (27.50)

417 (28.80)

15,516 (28.80)

307 (43.20)

136 (26.10)

136 (26.10)

53,40 (10.10)

392 (24.70)

240 (16.60)

294 (20.30)

5,469 (10.20)

263 (37.0)

84 (16.10)

91 (17.50)

4,008 ( 7.60)

349 (22.0)

203 (14.0)

246 (17.0)

4,105 ( 7.60)

252 (35.40)

76 (14.60)

80 (15.40)

8,176 (15.40)

367 (23.10)

238 (16.50)

271 (18.70)

8,299 (15.40)

244 (34.30)

76 (14.60)

76 (14.60)

6,103 (11.50)

357 (22.50)

229 (15.80)

257 (17.80)

6,168 (11.50)

292 (41.10)

108 (20.70)

118 (22.60)

4,065 ( 7.70)

448 (28.20)

307 (21.20)

320 (22.10)

4,167 ( 7.70)

346 (48.70)

164 (31.50)

159 (30.50)

Table 3. Descriptive Statistics
Unmatched
Sample
(N = 54,531)
Demographic and Clinical Characteristics
Age
Range
2 – 18
M (SD)
9.73 (4.73)
Sex/Gender
Male
53.40%
Female
46.60%
Ethnicity
Hispanic 46.10%
Non53.90%
Hispanic
Medicare/MediYes
60.60%
Cal Insurance
No
39.40%
Length of stay
Range
0 – 30
M (SD)
3.34 (4.10)
Number of Medications Ordered
Opioid Analgesics Range
0 – 11
M (SD)
1.94 (2.13)
Non-Opioid
Range
0–9
Analgesics
M (SD)
2.15 (1.28)

Anxiety Disorder
Analysis Matched
Sample (N = 2,892)

Mood Disorder
Analysis Matched
Sample (N = 1,042)

2 – 18
12.82 (4.25)
43.30%
56.70%
41.18%

2 – 18
14.29 (3.95)
62.00%
38.00%
38.00%

58.82%

62.00%

48.65%

57.20%

51.35%
0 – 30
6.01 (6.38)

42.80%
0 – 30
5.29 (6.04)

0 – 10
1.96 (2.16)

0 – 10
1.58 (2.11)

0–9

0–8

2.38 (1.54)

2.13 (1.44)

Table 4. Multiple Regression Model Results: Anxiety Disorder Diagnosis (N = 2,892)
Outcome Variables

Pain Severity

Opioid Analgesics

95% CI

Non-Opioid Analgesics

95% CI

95% CI

β

LL

UL

β

LL

UL

β

LL

UL

Maximum Pain Score
Anxiety Disorder
Diagnosis
Maximum Pain Score x
Anxiety Disorder
Diagnosis
Covariates
Year

---

---

---

0.60***

0.56

0.64

0.26***

0.22

0.30

0.13***

0.10

0.15

-0.09***

-0.11

-0.05

0.01

0.00

0.03

---

---

---

-0.07***

-0.09

-0.05

0.04**

0.03

0.05

0.03*

0.00

0.06

-0.05***

-0.06

-0.04

0.03*

0.02

0.04

Age

0.10***

0.07

0.13

0.01

0.00

0.02

-0.01

-0.02

0.00

Sex

-0.07***

-0.10

-0.05

0.10***

0.09

0.11

-0.02

-0.03

-0.01

Hispanic Ethnicity

0.04**

0.01

0.07

0.00

-0.02

0.01

-0.01

-0.02

0.00

Medicare/Medi-Cal

-0.03

-0.06

0.00

0.01

0.00

0.02

0.02

0.01

0.03

Length of Stay
Mood Disorder
Diagnosis
Bacterial and viral
infections
Blood diseases

0.11***

0.08

0.14

0.08***

0.07

0.09

0.07***

0.06

0.08

0.03

0.00

0.06

-0.11***

-0.13

-0.09

-0.01

-0.02

0.00

-0.02

-0.05

0.02

-0.01

-0.02

0.00

0.00

-0.01

0.01

-0.05**

-0.08

-0.01

0.03*

0.02

0.04

-0.05***

-0.06

-0.04

-0.01

-0.05

0.02

-0.06***

-0.08

-0.04

-0.04**

-0.05

-0.03

-0.07***

-0.10

-0.04

-0.08***

-0.09

-0.07

0.03*

0.02

0.04

0.00

-0.03

0.03

0.04**

0.03

0.05

-0.04**

-0.05

-0.03

-0.05**

-0.08

-0.01

0.01

-0.01

0.03

0.01

0.00

0.02

0.05**

0.02

0.08

0.04**

0.03

0.05

0.03*

0.02

0.04

0.02

-0.01

0.05

0.10***

0.09

0.11

0.08***

0.07

0.09

-0.04**

-0.08

-0.01

0.06***

0.05

0.07

0.00

-0.01

0.01

-0.02

-0.05

0.02

0.10***

0.09

0.11

0.01

0.00

0.02

-0.02

-0.05

0.01

0.16***

0.15

0.17

-0.02

-0.03

-0.01

Predictor Variables

Endocrine, nutritional,
and metabolic diseases
Diseases of the nervous
system
Diseases of the
circulatory system
Diseases of the
respiratory system
Diseases of the digestive
system
Diseases of the
musculoskeletal system
and connective tissue
Diseases of the
genitourinary system
Congenital
malformations,
deformations and
chromosomal
abnormalities
Injury, poisoning and
certain other
consequences

Other mental, behavioral
and neurodevelopmental
disorders
Opioid Analgesics

-0.09***

-0.12

-0.05

-0.14***

-0.16

-0.12

-0.04**

-0.05

-0.03

0.34***
0.30
0.37
0.10***
0.09 0.11
Non-Opioid Analgesics
------0.28***
0.24
0.31
0.18***
0.17
0.19
Note. Estimates represent standardized coefficients. CI = confidence interval; LL = lower limit; UL = upper limit.
*p < .05,**p< .01, ***p < .001

Table 5. Regression Model Results: Mood Disorder Diagnosis (N = 1,042)
Outcome Variables

Pain Severity

Opioid Analgesics

95% CI

Non-Opioid Analgesics

95% CI

95% CI

β

LL

UL

β

LL

UL

β

LL

UL

---

---

---

0.68***

0.60

0.76

0.31***

0.25

0.37

0.10***

0.06

0.15

-0.26***

-0.29

-0.20

-0.02

-0.04

0.02

---

---

---

0.05

0.00

0.10

0.04

0.02

0.06

Year

0.05*

0.00

0.10

-0.10***

-0.13

-0.07

-0.02

-0.04

0.00

Age

0.13***

0.08

0.18

-0.04

-0.07

-0.01

-0.02

-0.05

0.01

Sex

-0.12***

-0.16

-0.07

0.08**

0.05

0.11

-0.02

-0.04

0.00

Hispanic Ethnicity

-0.03

-0.08

0.01

0.01

-0.02

0.04

0.00

-0.02

0.02

Medicare/Medi-Cal

0.01

-0.03

0.06

-0.03

-0.06

0.00

0.07**

0.05

0.09

Length of Stay
Anxiety Disorder
Diagnosis
Bacterial and viral
infections
Blood diseases

0.12***

0.06

0.17

0.09***

0.07

0.11

0.00

-0.02

0.02

0.08**

0.04

0.13

-0.11***

-0.14

-0.08

0.01

-0.01

0.03

0.00

-0.05

0.06

0.01

-0.01

0.03

0.02

0.00

0.04

-0.08**

-0.13

-0.02

0.04

0.01

0.07

-0.01

-0.04

0.02

Endocrine, nutritional,
and metabolic diseases

0.01

-0.05

0.06

-0.20***

-0.23

-0.17

0.00

-0.03

0.03

Diseases of the nervous
system

-0.10***

-0.14

-0.05

-0.09**

-0.12

-0.06

0.03

0.01

0.05

Diseases of the
circulatory system

0.00

-0.05

0.06

0.06*

0.03

0.09

-0.02

-0.04

0.00

Diseases of the
respiratory system

-0.02

-0.07

0.03

0.00

-0.03

0.03

0.01

-0.01

0.03

0.04

-0.01

0.09

0.08**

0.05

0.11

0.03

0.01

0.05

0.03

-0.02

0.08

0.14***

0.12

0.16

0.01

-0.01

0.03

0.00

-0.06

0.05

0.08***

0.06

0.10

-0.03

-0.05

-0.01

-0.05*

-0.11

0.00

0.10***

0.08

0.12

0.02

0.00

0.04

-0.04

-0.09

0.01

0.16***

0.14

0.18

-0.04

-0.06

-0.02

Predictor Variables
Maximum Pain Score
Mood Disorder
Diagnosis
Maximum Pain Score x
Mood Disorder
Diagnosis
Covariates

Diseases of the digestive
system
Diseases of the
musculoskeletal system
and connective tissue
Diseases of the
genitourinary system
Congenital
malformations,
deformations and
chromosomal
abnormalities
Injury, poisoning and
certain other
consequences

Other mental, behavioral
and neurodevelopmental
disorders
Opioid Analgesics

-0.01

-0.06

0.04

-0.12***

-0.15

-0.09

-0.05*

-0.07

-0.03

0.30***

0.24

0.36

---

---

---

0.14***

0.11

0.17

Non-Opioid Analgesics
0.33***
0.27
0.38
0.19***
0.17
0.21
------Note. Estimates represent standardized coefficients. CI = confidence interval; LL = lower limit; UL = upper limit.
*p < .05,**p< .01, ***p < .001

